PSMA is both a predictor of disseminated disease and a therapy target since PSMA expression increases with the severity of the disease (e.g., tumor grade, metastatic disease, reoccurrence, and androgen-independence) [5]. The gene discussed is FOLH1; the disease is metastatic neoplasm.